EV
Evangelos
Community Contributor
Member since 2023
Views2kTotal number of views
Followers38Total number of followers
Comments0Total number of comments
No bio added yet
No link added
Bristol Myers Squibb (BMY): Undervalued Opportunity or Value Trap? A Deep Dive into 2024 Earnings and Fair Value
Fourth Quarter 2024 Highlights: Total Revenues: $12.3 billion, an 8% increase from the same period in 2023. GAAP Earnings Per Share (EPS): $0.04, a significant decrease from $0.87 in Q4 2023.Read more
539
users have viewed this narrative3users have liked this narrative
0users have commented on this narrative
19users have followed this narrative
EV
US$65
5.8% undervalued intrinsic discount
Evangelos's Fair Value
Revenue
2.43% p.a.
Profit Margin
14.81%
Future PE
22.23x
Price in 2030
US$87.86
Medtronic Stock: A Compelling Buy for Value and Income Investors as Robotics, Innovation Catalysts Ignite Upside to $105+
Strengths and Competitive Advantages: Diverse Product Portfolio: Medtronic operates across four key segments—Cardiovascular, Medical-Surgical, Neuroscience, and Diabetes—providing revenue stability and reducing dependency on any single product line. This diversification surpasses more specialized competitors like Boston Scientific (focused on cardiovascular) or Intuitive Surgical (robotics).Read more
1.4k
users have viewed this narrative10users have liked this narrative
5users have commented on this narrative
22users have followed this narrative
EV
US$95
3.8% overvalued intrinsic discount
Evangelos's Fair Value
Revenue
5.15% p.a.
Profit Margin
13%
Future PE
27.57x
Price in 2030
US$141.16